Key updates
ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced results for
the fourth quarter and full year 2016 and provided business
updates.
“2017 is going to be an important year for ProQR and the 3
products under development. Our investigational product for cystic
fibrosis (CF), QR-010, is scheduled to complete a phase 1b trial,
and is expected to advance into a phase 2 study next year. After
the recent success in our NPD biomarker study, showing clinically
meaningful drug activity in homozygous F508del CF patients, we look
forward to developing this product candidate with the aim of
getting it to patients as quickly as possible,” said Daniel A. de
Boer, Chief Executive Officer of ProQR. “QR-110, our second
development program targeting Leber’s congenital amaurosis Type 10
(LCA 10), is scheduled to start a Phase 1b/2 trial in patients this
year. QR-313 for dystrophic epidermolysis bullosa (DEB) is going
through IND enabling work to initiate a clinical trial next year. I
am excited to see that we are making good progress on our mission
of bringing life changing therapies to patients in need.”
Business update and upcoming corporate
milestones
- ProQR provides an update on enrollment in the Phase 1b
study of QR-010. Cohort 6 was successfully completed and
cohort 7 is currently being conducted with only cohort 8 remaining
to complete the study. The company plans to advance the program
into a phase 2 trial in 2018. At the time of ECFS (June 7-10 2017)
the company will provide a next update on enrollment in the study.
The study is expected to have topline data in mid-2017.The Phase 1b
study is designed to enroll a total of 64 homozygous adult F508del
patients that have a relatively good lung function (ppFEV1
>70%). Patients receive either a single dose of QR-010 through
inhalation, or 12 doses over the course of 4 weeks. 4 different
dose groups are studied in this placebo controlled trial. Although
exploratory efficacy outcomes are measured, the Phase 1b study is
designed to evaluate safety and tolerability and identify an
appropriate dose for subsequent Phase 2 and 3 studies, it is not
powered to demonstrate efficacy in a statistical significant
manner. Meanwhile ProQR is preparing for the start of a phase 2
program in 2018.
- ProQR expects to start the Phase 1b/2 clinical trial
with QR-110 in LCA 10 patients in H1 2017. In this trial
QR-110 will be administered repeatedly through intravitreal
injections. Over a year 4 doses will be given in 3 different dose
groups. The trial is designed to enroll a total of 6 adult and 6
pediatric patients.
Corporate highlights 2016
- QR-010 for F508del cystic fibrosis-
QR-010, ProQR’s lead molecule, demonstrated proof-of-concept
activity in patients. Positive results from key biomarker clinical
study were presented during the North American Cystic
Fibrosis conference (NACFC) October 26 – 29, 2016 the
company presented positive results from PQ-010-002, a
proof-of-concept study demonstrating that QR-010 restores CFTR
function in patients homozygous for F508del. CFTR is the protein
channel that is defective in patients with CF, and presence or
absence of function of CFTR can be measured by an important
biomarker called the nasal potential difference (NPD) assay.
Following 4 weeks of topical therapy, QR-010 improved the
CFTR-mediated total chloride response, a direct measure of CFTR
function. This was confirmed by the restoration of other indicators
of CFTR function, such as the sodium channel activity. In subjects
that were compound heterozygous for the F508del mutation, no
meaningful difference was measured. QR-010 was observed to be safe
and well-tolerated in all subjects.- QR-010
demonstrated safety in single ascending dose cohorts of the Phase
1b study: During NACFC the company also announced that
clinical study PQ-010-001 completed all four single-dose cohorts
and blinded safety data from all cohorts was shared. PQ-010-001 is
a placebo-controlled trial in subjects with CF homozygous for
F508del enrolling 64 patients in a total of 8 cohorts (four
single-ascending doses and four multiple-ascending doses), where
QR-010 is administered through the PARI eFlow nebulizer. QR-010 was
observed to be safe and well-tolerated in all single dose cohorts.
The multiple dose cohorts in this study are ongoing and we are
currently enrolling cohort 7. Topline safety, tolerability,
pharmacokinetics and exploratory efficacy data from this study are
expected in mid-2017.- QR-010 granted Fast Track
designation: In July 2016, QR-010 received a Fast
Track designation by the US Food and Drug
Administration (FDA). Drugs that are under development for
serious conditions and have the potential to fulfill an unmet
medical need can receive this designation. It was established with
the intention to bring promising drugs to patients sooner by
facilitating the development with more
frequent FDA interactions and expediting the review
process.- QR-010 diffuses through and is stable in CF
mucus: During the 12th Annual Meeting of the
Oligonucleotide Therapeutics Society (OTS) September 25 – 28, 2016
the company presented a poster that summarized some of the exciting
pre-clinical work showing repeated nebulization of QR-010 did not
change the diffusion speed of QR-010 in in vitro models of CF-like
mucus and that QR-010 was stable in the presence of clinically
relevant levels of several CF standard-of-care therapies. This is
an important step towards establishing the potential delivery of
QR-010 through CF mucus.
- QR-110 for inherited blindness Leber’s congenital
amaurosis Type 10- QR-110, ProQR’s molecule
for a rare form of congenital blindness, demonstrates important
pre-clinical activity. At the 2016 Annual Meeting of
the Association for Research in Vision and
Ophthalmology (ARVO) the company presented pre-clinical data
for QR-110 for LCA 10. QR-110 is a single-stranded, chemically
modified RNA oligonucleotide designed to suppress the cryptic
splice site created by the p.Cys998X mutation resulting in mRNA
that codes for a wild-type CEP290 protein. Following intravitreal
injection in vivo, QR-110 was observed to reach the outer
nuclear layer of the retina, the target tissue. QR-110 was also
observed to increase wild-type mRNA in cells with the p.Cys998X
mutation. During the 12th Annual Meeting of the Oligonucleotide
Therapeutics Society (OTS), the company also presented a poster
that showed data demonstrating that QR-110 can restore CEP290 mRNA
and protein levels in primary LCA 10 compound heterozygous patient
cells and homozygous optic cups in a dose dependent manner. Based
on this data, and other extensive pre-clinical work, the company
plans to start a first-in-human study in adult and pediatric
subjects in the first half of 2017.- QR-110 granted
Orphan drug designation from FDA and EMA: QR-110, a
first-in-class oligonucleotide therapy in development for patients
with LCA 10 due to the p.Cys998X mutation received orphan drug
designation (ODD) from both the U.S. Food and Drug
Administration (FDA) and the European Medicines
Agency (EMA). ODD in the U.S. and the European
Union confers a special status for investigational drugs that
are being developed for rare diseases.
- QR-313 for dystrophic epidermolysis bullosa due to an
exon 73 mutation- QR-313, ProQR’s molecule
for a rare disease, dystrophic epidermolysis bullosa, advances to
pre-clinical development: In the second half of the year,
the company advanced its product candidate for the third program,
QR-313 (previously named QRX-313) into pre-clinical development for
the treatment of DEB. QR-313 is an RNA oligonucleotide designed to
induce the exclusion of a part of the RNA (exon skipping) that
contains a disease causing mutation with the aim to restore
functional C7 protein and with that the anchoring fibrils that bind
the layers of skin together. QR-313 is the second program to be
added to the pipeline behind the CF and LCA 10 programs from
ProQR’s internal innovation (discovery) unit. The clinical program
for QR-313 is expected to start in 2018.
- ProQR’s inaugural R&D day provides key updates on
drug pipeline: On March 14th the company
presented at an inaugural R&D Day in New York where
ProQR executives as well as external key opinion leaders presented
more information on ProQR’s pipeline products including programs
for CF, LCA 10, Usher syndrome, Fuchs endothelial corneal
dystrophy, DEB and Alzheimer’s disease.
- James Shannon, former CMO at GSK joins ProQR:
ProQR strengthened its Supervisory Board with the appointment
of James Shannon, MD in June 2016. James was the former
Chief Medical Officer at GlaxoSmithKline and Global Head
of Pharma Development at Novartis. James currently
serves on a number of boards that include Mannkind Corp.,
myTomorrows and Immodulo. We believe that James’ broad knowledge
and expertise in drug development and pharma will be of significant
value to and further strengthens the Supervisory Board that
includes several experienced biopharma executives like Dinko
Valerio, founding CEO at Crucell and Henri Termeer, former CEO at
Genzyme.
Financial highlights
At December 31, 2016, ProQR held cash and cash equivalents of
€59.2 million, compared to €94.9 million at December 31, 2015. The
decrease in cash was driven by operating expenses, partially offset
by receipt of grants, change in working capital and foreign
currency gains. Net cash used in operating activities during the
three month period and full year ended December 31, 2016 was €7.3
million and €34.2 million respectively, compared to €6.8 million
and €24.2 million for the same period last year.
Research and development costs increased to €8.1 million for the
quarter ended December 31, 2016 from €6.5 million for the same
period in 2015. Research and development costs for the year ended
December 31, 2016 were €31.9 million, compared to €23.4 million for
the same period in 2015. The increase was primarily driven by the
advancement of our pipeline, which included clinical development of
QR-010 for CF, preparations for the start of the first clinical
trial of QR-110 for LCA 10, and pre-clinical development activities
of QR-313 for DEB.
General and administrative costs increased to €2.3 million for
the quarter ended December 31, 2016 from €2 million for the same
period in 2015. General and administrative costs for the year ended
December 31, 2016 were €9.5 million, compared to €6.8 million
for the same period in 2015, which were primarily driven due to
increased investments in our facilities and our support
organization.
Net result for the three month period ended December 31, 2016
was a €8.8 million loss or €0.38 per share, compared to a €6.1
million loss or €0.26 per share for the same period in 2015. Net
loss for the year ended December 31, 2016 was €39.1 million or
€1.68 per share, compared to €20.8 million, or €0.89 per share for
the same period ended December 31, 2015. For further financial
information for the period ending December 31, 2016, please refer
to the financial statements appearing at the end of this
release.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the
creation of transformative RNA medicines for the treatment of
severe orphan diseases such as cystic fibrosis and Leber’s
congenital amaurosis. Based on our unique proprietary RNA repair
platform technologies we are growing our pipeline with patients and
loved ones in mind. *Since 2012*
About QR-010
QR-010 is a first-in-class RNA-based oligonucleotide designed to
address the underlying cause of the disease by targeting the mRNA
in CF patients that have the F508del mutation. The F508del mutation
is a deletion of three of the coding base pairs, or nucleotides, in
the CFTR gene, which results in the production of a misfolded CFTR
protein that does not function normally. QR-010 is designed to bind
to the defective CFTR mRNA and to restore CFTR function. QR-010 is
designed to be self-administered via an optimized eFlow® Nebulizer
(PARI Pharma GmbH). eFlow® is a small, handheld aerosol delivery
device which nebulizes QR-010 into a mist inhaled directly into the
lungs. QR-010 has been granted orphan drug designation in the
United States and the European Union and fast-track status by the
FDA. The QR-010 project has received funding from the European
Union’s Horizon 2020 research and innovation programme under grant
agreement No 633545.
About QR-110
QR-110 is a first-in-class RNA-based oligonucleotide designed to
address the underlying cause of Leber’s congenital amaurosis Type
10 due to the p.Cys998X mutation in the CEP290 gene. The p.Cys998X
mutation is a substitution of one nucleotide in the pre-mRNA that
leads to aberrant splicing of the mRNA and non-functional CEP290
protein. QR-110 is designed to restore wild-type CEP290 mRNA
leading to the production of wild-type CEP290 protein by binding to
the mutated location in the pre-mRNA causing normal splicing of the
pre-mRNA. QR-110 is intended to be administered through
intravitreal injections in the eye and has been granted orphan drug
designation in the United States and the European Union.
About QR-313
QR-313 is a first-in-class RNA-based oligonucleotide designed to
address the underlying cause of dystrophic epidermolysis bullosa
(DEB) due to mutations in exon 73 of the COL7A1 gene. Mutations in
this exon can cause loss of functional collagen type VII (C7)
protein. Absence of C7 results in the loss of anchoring fibrils
that normally link the dermal and epidermal layers of the skin
together. QR-313 is designed to exclude exon 73 from the mRNA (exon
skipping) and produce truncated but functional C7 protein and
thereby restores functionality of the anchoring fibrils.
2016 Annual Reports
The consolidated statement of financial position of ProQR
Therapeutics N.V. as of December 31, 2016 and December 31, 2015,
the consolidated statements of comprehensive loss for the years and
the three month periods ended December 31, 2016 and 2015, the
related consolidated statement of changes in equity for the years
ended December 31, 2016 and 2015 and the consolidated statements of
cash flows for years and three months periods ended December 31,
2016 and 2015 as presented in this press release are unaudited.
ProQR Therapeutics N.V. will publish its 2016 Annual Report on Form
20-F, Statutory Annual Report, and Compensation Report later in Q1
2017. The reports will be published on our website at
www.proqr.com.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All
statements other than statements of historical fact are
forward-looking statements, which are often indicated by terms such
as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,”
“intend,” “look forward to,” “may,” “plan,” “potential,” “predict,”
“project,” “should,” “will,” “would” and similar expressions.
Forward-looking statements are based on management’s beliefs and
assumptions and on information available to management only as of
the date of this press release. These forward-looking statements
include, but are not limited to, statements regarding QR-010,
QR-110 and QR-313, including our development plans for these
product candidates and their therapeutic potential, statements
regarding our ongoing and planned discovery and development of
existing and future product candidates, statements regarding the
expected timing of results from our clinical studies, statements
regarding Fast Track and orphan designations, and statements
regarding the appointment of Dr. Shannon to our Supervisory Board.
Our actual results could differ materially from those anticipated
in these forward-looking statements for many reasons, including,
without limitation, risks associated with our clinical development
activities, manufacturing processes and facilities, regulatory
oversight, product commercialization, intellectual property claims,
and the risks, uncertainties and other factors in our filings made
with the Securities and Exchange Commission, including certain
sections of our annual report filed on Form 20-F. Given these
risks, uncertainties and other factors, you should not place undue
reliance on these forward-looking statements, and we assume no
obligation to update these forward-looking statements, even if new
information becomes available in the future.
Contact:Sariette WitteInvestor RelationsT: +1
213 261 8891ir@proqr.com
PROQR THERAPEUTICS N.V. |
Unaudited Condensed Consolidated Statement of Financial
Position |
|
|
|
|
|
|
|
December 31,2016 |
|
December 31,2015 |
|
|
€ 1,000 |
|
€ 1,000 |
Assets |
|
|
|
|
Current assets |
|
|
|
|
Cash and cash equivalents |
|
59,200 |
|
94,865 |
Prepayments and other receivables |
|
2,420 |
|
1,948 |
Social securities and other taxes |
|
395 |
|
956 |
|
|
|
|
|
|
|
|
|
|
Total current assets |
|
62,015 |
|
97,769 |
|
|
|
|
|
Property, plant and equipment |
|
3,438 |
|
2,199 |
Intangible assets |
|
90 |
|
141 |
|
|
|
|
|
Total assets |
|
65,543 |
|
100,109 |
|
|
|
|
|
Liabilities and shareholders' equity |
|
|
|
|
Current liabilities |
|
|
|
|
Finance lease liabilities |
|
-- |
|
15 |
Trade payables |
|
328 |
|
885 |
Social securities and other taxes |
|
312 |
|
235 |
Pension premiums |
|
13 |
|
16 |
Deferred income |
|
-- |
|
144 |
Other current liabilities |
|
6,057 |
|
4,191 |
|
|
|
|
|
Total current liabilities |
|
6,710 |
|
5,486 |
|
|
|
|
|
Borrowings |
|
5,697 |
|
4,824 |
|
|
|
|
|
Total liabilities |
|
12,407 |
|
10,310 |
|
|
|
|
|
Shareholders' equity |
|
|
|
|
Shareholders' equity |
|
53,136 |
|
89,799 |
|
|
|
|
|
Total liabilities and shareholders' equity |
|
65,543 |
|
100,109 |
|
|
|
|
|
PROQR THERAPEUTICS N.V. |
Unaudited Condensed Consolidated Statement of Profit or
Loss and OCI |
(€ in
thousands, except share and per share data) |
|
|
|
|
|
|
|
|
Three month period ended December
31, |
|
Year ended December 31, |
|
|
2016 |
|
|
2015 |
|
|
2016 |
|
|
2015 |
|
|
|
€ 1,000 |
|
|
€ 1,000 |
|
|
€ 1,000 |
|
|
€ 1,000 |
|
Other income |
|
103 |
|
|
958 |
|
|
1,828 |
|
|
3,235 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Research
and development costs |
|
(8,100 |
) |
|
(6,494 |
) |
|
(31,923 |
) |
|
(23,401 |
) |
General
and administrative costs |
|
(2,260 |
) |
|
(1,999 |
) |
|
(9,478 |
) |
|
(6,837 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
Total operating costs |
|
(10,360 |
) |
|
(8,493 |
) |
|
(41,401 |
) |
|
(30,238 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
Operating result |
|
(10,257 |
) |
|
(7,535 |
) |
|
(39,573 |
) |
|
(27,003 |
) |
Finance
income and expense |
|
1,438 |
|
|
1,409 |
|
|
470 |
|
|
6,171 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Result before corporate income taxes |
|
(8,819 |
) |
|
(6,126 |
) |
|
(39,103 |
) |
|
(20,832 |
) |
Income
taxes |
|
|
|
-- |
|
|
|
|
|
-- |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss attributable to equity holders of the
Company |
|
(8,819 |
) |
|
(6,126 |
) |
|
(39,103 |
) |
|
(20,832 |
) |
Other
comprehensive income |
|
(16 |
) |
|
1 |
|
|
(16 |
) |
|
1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total comprehensive loss (attributable to equity holders of
the Company) |
|
(8,835 |
) |
|
(6,125 |
) |
|
(39,119 |
) |
|
(20,831 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
Share information |
|
|
|
|
|
|
|
|
|
|
|
Weighted
average number of shares outstanding1 |
|
23,346,856 |
|
|
23,345,860 |
|
|
23,346,507 |
|
|
23,343,262 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share attributable to the equity holders of
the Company (expressed in Euro per share) |
|
|
|
|
|
|
|
|
|
|
|
Basic
loss per share1 |
|
(0.38 |
) |
|
(0.26 |
) |
|
(1.68 |
) |
|
(0.89 |
) |
Diluted
loss per share1 |
|
(0.38 |
) |
|
(0.26 |
) |
|
(1.68 |
) |
|
(0.89 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
- For this period presented in these financial statements, the
potential exercise of share options is not included in the diluted
earnings per share calculation as the Company was loss-making in
all periods. Due to the anti-dilutive nature of the outstanding
options, basic and diluted earnings per share are equal in this
period.
PROQR THERAPEUTICS N.V. |
Unaudited Condensed Consolidated Statement
of Changes in Equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number ofshares |
|
Total
ShareCapital |
|
Share Premium |
|
Equity Settled
Employee Benefit
Reserve |
|
TranslationReserve |
|
|
Accumulated
Deficit |
|
|
Total Equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 1,000 |
|
€ 1,000 |
|
€ 1,000 |
|
€ 1,000 |
|
|
€ 1,000 |
|
|
€ 1,000 |
|
Balance at January 1, 2015 |
|
23,338,154 |
|
934 |
|
123,581 |
|
687 |
|
-- |
|
|
(15,798 |
) |
|
109,404 |
|
Net
loss |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
(20,832 |
) |
|
(20,832 |
) |
Other
comprehensive income |
|
-- |
|
-- |
|
-- |
|
-- |
|
1 |
|
|
-- |
|
|
1 |
|
Recognition of share-based payments |
|
-- |
|
-- |
|
-- |
|
1,212 |
|
-- |
|
|
-- |
|
|
1,212 |
|
Share
options exercised |
|
7,811 |
|
0 |
|
14 |
|
-- |
|
-- |
|
|
-- |
|
|
14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2015 |
|
23,345,965 |
|
934 |
|
123,595 |
|
1,899 |
|
1 |
|
|
(36,630 |
) |
|
89,799 |
|
Net
loss |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
(39,103 |
) |
|
(39,103 |
) |
Other
comprehensive income |
|
-- |
|
-- |
|
-- |
|
-- |
|
(16 |
) |
|
-- |
|
|
(16 |
) |
Recognition of share-based payments |
|
-- |
|
-- |
|
-- |
|
2,454 |
|
-- |
|
|
-- |
|
|
2,454 |
|
Share
options exercised |
|
891 |
|
0 |
|
2 |
|
-- |
|
-- |
|
|
-- |
|
|
2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2016 |
|
23,346,856 |
|
934 |
|
123,597 |
|
4,353 |
|
(15 |
) |
|
(75,733 |
) |
|
53,136 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PROQR THERAPEUTICS N.V. |
Unaudited Condensed Consolidated Statement of Cash
Flows |
|
|
|
|
|
|
|
Three month period ended December
31, |
|
|
Year ended December 31, |
|
|
|
2016 |
|
|
2015 |
|
|
2016 |
|
|
2015 |
|
|
|
€ 1,000 |
|
|
€ 1,000 |
|
|
€ 1,000 |
|
|
€ 1,000 |
|
Cash flows from operating activities |
|
|
|
|
|
|
|
|
|
|
|
|
Net
result |
|
(8,835 |
) |
|
(6,125 |
) |
|
(39,119 |
) |
|
(20,831 |
) |
Adjustments for: |
|
|
|
|
|
|
|
|
|
|
|
|
—
Depreciation |
|
267 |
|
|
142 |
|
|
1,245 |
|
|
480 |
|
—
Share-based compensation |
|
537 |
|
|
293 |
|
|
2,454 |
|
|
1,212 |
|
—
Financial income and expenses |
|
(1,438 |
) |
|
(1,409 |
) |
|
(470 |
) |
|
(6,171 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Changes
in working capital |
|
1,984 |
|
|
165 |
|
|
1,433 |
|
|
637 |
|
Cash used
in operations |
|
(7,485 |
) |
|
(6,934 |
) |
|
(34,457 |
) |
|
(24,673 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Corporate
income tax paid |
|
-- |
|
|
-- |
|
|
-- |
|
|
-- |
|
Interest
received/(paid) |
|
159 |
|
|
160 |
|
|
236 |
|
|
441 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash used in operating activities |
|
(7,326 |
) |
|
(6,774 |
) |
|
(34,221 |
) |
|
(24,232 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flow from investing activities |
|
|
|
|
|
|
|
|
|
|
|
|
Purchases
of intangible assets |
|
-- |
|
|
-- |
|
|
-- |
|
|
(28 |
) |
Purchases
of property, plant and equipment |
|
(44 |
) |
|
(203 |
) |
|
(2,539 |
) |
|
(1,296 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash used in investing activities |
|
(44 |
) |
|
(203 |
) |
|
(2,539 |
) |
|
(1,324 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flow from financing activities |
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds
from exercise of share options |
|
-- |
|
|
0 |
|
|
2 |
|
|
14 |
|
Proceeds
from borrowings |
|
177 |
|
|
386 |
|
|
370 |
|
|
1,640 |
|
Redemption of financial lease |
|
-- |
|
|
(7 |
) |
|
(15 |
) |
|
(34 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash generated by financing activities |
|
177 |
|
|
379 |
|
|
357 |
|
|
1,620 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net increase/(decrease) in cash and cash
equivalents |
|
(7,193 |
) |
|
(6,598 |
) |
|
(36,403 |
) |
|
(23,936 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Currency
effect cash and cash equivalents |
|
1,472 |
|
|
1,451 |
|
|
738 |
|
|
6,065 |
|
Cash and
cash equivalents, at beginning of the period |
|
64,921 |
|
|
100,012 |
|
|
94,865 |
|
|
112,736 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at the end of the
period |
|
59,200 |
|
|
94,865 |
|
|
59,200 |
|
|
94,865 |
|
ProQR Therapeutics NV (NASDAQ:PRQR)
Historical Stock Chart
From Aug 2024 to Sep 2024
ProQR Therapeutics NV (NASDAQ:PRQR)
Historical Stock Chart
From Sep 2023 to Sep 2024